☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
P-III study
Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis
July 16, 2021
GSK Initiates P-III Study of GSK3511294 (GSK'294) for the Treatment of Severe Asthma
March 18, 2021
Novartis' Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study
March 10, 2021
Merck to Acquire OncoImmune for $425M
November 24, 2020
Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six
October 1, 2020
Henlius Presents P-III Data of HLX04 (biosimilar- bevacizumab) at CSCO 2020
September 20, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.